Member Info for B2HS2L

Could posters please refrain from making finger in the air cash at bank estimates in future, simply because it seems likely Novacyt income from assay sales and instruments must be increasing in line with other companies statements of being very busy lately.
The cost of setting up Novacyt US Inc cannot possibly be established because insufficient info concerning these costs is available in the public domain.

However, I accept we are totally committed to setting the company up after Raimondo's statement :
"The focus for us going forward is to establish ourselves in the America's especially the US, and also to expand our global footprint, focusing on one of the key European markets."

I'll raise a glass tonight to Kevin and Raimondo's efforts to get this business set up on a strong footing, such that we can see some action soon.

Poidster -

I would say don't make further decisions until after the AGM, and - if quorate - the EGM.

I expect further discussion of the subjects within the video at this meeting.
a) A new CEO should have something to say on future priorities, - possibly Marketing and sales.
b) Material that amplifies the video could be discussed.
The presentation backs up what appears in the 22.06.2021 RNS Novacyt-full-year-2020-results 'Strategy Update', so I'm thinking AD might further amplify at AGM.

Bullet points found within the Strategy Update:
• Investment in R&D to deliver new products in the respiratory and transplant
bacterial and viral diagnostic markets
• Investment in commercial infrastructure to establish a direct sales force in key
markets in Europe and the US
• Selective product/technology and company acquisitions to generate additional
revenues and expand its core capabilities whilst maintaining attractive margins
• Investment in developing new IP portfolio to enhance and secure future value

As you say sp in the bin, but not for much longer if M&A activity arrives.

The video contains this statement of intent that will wake up the competition:
"Guillermo Raimondo (3:06)

The focus for us going forward is to establish ourselves in the America's especially the US, and also to expand our global footprint, focusing on one of the key European markets."

IMO I expect US based competitors to allow us to invest in Novacyt US Inc as we have stated, then make any offer only when it becomes clear our global and/or US market share is increasing markedly.
If little increase in market share, then any predator offer might be because they covet our instrumentation, R&D, and Bioinformatics teams, to say nothing of the catalogue of Primer design assays and Microgen LFT's etc.

Novacyt cannot be ignored by competitors because the speed with which we innovate is a clear and present danger to competitor profits, if not now, then very possibly soon. The term 'market disruptive', applies to many of our products such as Q16/Q32, PROmate, SNP-sig assays, Escapeplex et al. They need more marketing spend to wake the market up to Navacyt's potential, and that will happen now DA has arrived.

EXMEX, - agreed. It sure as hell isn't France :)

I didn't find co-prep mentioned on the below link EXMEX, it is due to launch this month I think?

Glad I'm not short this weekend, - somebody else's headache ha ha!!

Kevin Crittenton (3:19)

Novacyt is a technology leader with excellent products, and our contribution to the global pandemic has shown that we can make a larger mark in the diagnostic industry. The Americas is an important market for us. Naturally we want to grow our business here. In the future we will have a US commercial operations with more resources. We also have a direct sales force that will be focussing on expanding our distributor network.
And we will also have a larger product portfolio that is regulatory approved in the US and South America.

Graham Mullis (3:58)

The diagnostic market is a very large and an important part of the overall healthcare market. And in fact, it is highly fragmented and there are some significant unmet needs within those markets, which we can focus on.

Paul Oladimeji (4:12)

One of the biggest challenges that faces clinicians and the testing laboratories is the turnaround for the patient sample being turned into a result.
Novacyt are at the forefront of delivering near patient testing solutions, which reduce the need for the elaborate infrastructure that is required by those centralised laboratories. Now, this does'nt have to solely be for Covid-19. We're also working to apply this to fields like transplantation and other niche fields like antimicrobial resistance pathogens. This is how Novacyt can apply these innovations in other public health challenges.

Gemma Stokes (4:53)

Sequencing technology has advanced hugely in the last decade. So one project we're looking into is speeding up nucleic acid detection from around an hour to about ten minutes. The other project is so that we can detect more assays in one tube, which will give a lot more flexibility to our customers. Of course our surveillance programme will continue, but we're also looking at ways of automating that completely so that we can focus on these other projects.

Kevin Crittenton (5:24)

What I'm excited about is being a part of the Novacyt family and legacy in bringing innovative technology to the market place and being able to make a difference in the diagnostic market and the way that we can help to improve healthcare.

Graham Mullis (5:45)

The challenge for the business as we continue to grow is to ensure that it maintains at it's heart those core values of being nimble, being dynamic and really driving this can do attitude.
Whilst that will be supplemented by lots of structure as the business grows, that will remain the heart of Novacyt today and tomorrow.

Graham Mullis:
Novacyt is a global developer and manufacturer of clinical diagnostic products. The markets that we focus on today include infectious diseases and more specifically, respiratory and transplantation markets. We've been at the centre of a number of epidemics and pandemics around the world. And then of course more recently with Covid-19. So our ability to respond very quickly to the market is the reason why we were able to be one of the first companies to bring a fully qualified Covid-19 test to the market.

Guillermo Raimondo (0:44)

We have a full range of Covid-19 solutions from previous technologies like PCR, LFT and ELISA, that we can deploy easily for other infectious diseases. Our spectrum of customers is wide ranging from world government to private health care to laboratories big and small. And we through our global network, were able to ship our products to over 140 countries worldwide.

Paul Oladimeji (1:11)

Novacyt has a very extensive range of products, including human pathogen detection, veterinary and agriculture testing, oncology and genotyping, just to name a few. What makes these products unique is the high - advanced in silico analysis, which includes mutation modelling and analysis sequence structures. All of this is the foundation of our molecular diagnostics.

One of the key aspects of product development to the Novacyt group is our bioinformatics department. - Now they are not only responsible for the initial stages of our product development activities, but when the product is launched and it's in the market place, they're responsible for our post market surveillance.

GEMMA STOKES (2:05)

The bioinformatics team played a vital role in responding to the pandemic. We designed the original and I think the first commercially available assay to target this new coronavirus.
And we needed to be absolutely sure that a mutation wasn't going to arise within the primers or probes of that assay. So we developed one of the most comprehensive genome surveillance programmes in the diagnostic industry to check the sequences daily that we put onto the database to ensure that our assay would still work. And to date we have analysed over two million sequences.
What we've seen is unprecedented amounts of sequence information being made publically available. And going forward this is going to put the clinical diagnostic industry in a much stronger position to deal with emerging diseases and making sure we have the right tools and the right information to help combat any future pandemics.

Guillermo Raimondo (3:06)

The focus for us going forward is to establish ourselves in the America's especially the US, and also to expand our global footprint, focusing on one of the key European markets.

So you'll be starting this proposed about face in the tone of your posts I assume.

Well done, I knew you had it in you.

Yes Larry 20% to achieve an EGM quorum.

I'm drawing attention to the difference in agreement with each resolution required at AGM and EGM.

Simple majority of > 50% at AGM, and >66.66% at EGM.

Larry - As you say AGM will happen Monday.

From Articles of Association - Article 19:

"The ordinary general meeting of shareholders takes its decisions based on a majority of votes of the
shareholders present or represented."

As for the EGM for which we are waiting for Mandy to count voters and votes:

"The special general meeting (egm) of shareholders takes its decisions based on a majority of two thirds of
the votes of the shareholders present or represented."

So EGM resolutions will require a higher level of support.

Many other companies currently reporting good sales.
Why sell up when things are just warming up.
Don't advise us to sell because you don't want us to enjoy the profits you denied yourself.

https://www.linkedin.com/feed/update/urn:li:activity:6854447215784534016/

20 mins ago - 2% short of quorate.

https://uk.investing.com/news/coronavirus/britains-covid19-situation-stable--health-minister-2484195

LONDON (Reuters) - Britain's defences against COVID-19 are working and the pandemic situation is currently stable, health minister Sajid Javid said on Thursday.

"Overall things feel quite stable at this point. The numbers are a bit up, a bit down over the last few weeks," he told Times Radio.

"Our primary defences against this virus are working."

Britain reported 42,776 new COVID-19 cases on Wednesday, the highest number since mid-July, and 136 more deaths within 28 days of a positive test, official data showed.

+++

Suggested rephrase
Britain's only defence against COVID-19 (vaccinations) are working but the pandemic situation is currently unstable.

The only option will be lockdown if a new variant starts evading the vaccines.

+++

Great to see our ministers are still putting themselves out trying to improve the health of the UK population.

Boris on holiday and Sajid Javid in denial until the boss gets back and tells him what to do next.

Thanks for the info in your post Poidster.
We had view of a freedom of information request letter, that stated that at the time of the request, 170 instruments had been delivered.
We know that the Sept 28th 2020 contract phase 1 should have delivered 300 instruments, and the RNS stated "This first phase of the contract will involve the immediate deployment of 300 PCR instruments".

So if GM says 300 were immediately deployed I believe him, as he does not do fake news, but RNS uses the future tense, 'will'.

What do your observations tell you, are there 170 in use, or 300 (nearly twice as many)?

If your not comfortable with a guess that's fine, but any assistance you can provide would be good.
It would be good to estimate how many assay kits per month NHS are capable of processing with instruments in constant use..

Complete with Tiller hopefully ;)

"However I’ll stick to my version, as copied & pasted from the management report."

DH - You definitely mean your interpretation of the management report statement.

If the company starts RNSing contracts, then one day we will be advised company A has ordered product B.
And that will be the first we heard that product B has been launched.
With you all the way ALB and kaeren.

In case this has not been posted before:

source: https://www.gov.uk/government/publications/nhs-test-and-trace-how-we-test-your-samples/nhs-test-and-trace-how-we-test-your-samples

NHS Test and Trace: how we test your samples
Updated 29 July 2021

"Automation and technology
As well as building a vast new laboratory network, NHS Test and Trace has invested in new innovative testing technology which means we can operate faster and with increased capacity and develop a flexible pandemic response infrastructure that can respond to surges in demand.

This includes LGC’s EndPoint PCR (EPCR) testing workflow for COVID-19, which has ultra-high capacity and is used in our 2 largest laboratories, Royal Leamington Spa and Milton Keynes"
+++

So not likely that COVID-HT Direct or 3G is involved in these lighthouse labs.

https://twitter.com/NovacytGroup/status/1446542663449251846

Virtual meeting of American Society of Human Genetics.

Novacyt Group
@NovacytGroup
·
12h
The #Novacyt team are excited to be attending #ASHG21 this year.
Our experts will be attending the event and look forward to discussing all things PCR and PROmate® with you there.
We can’t wait to meet you all! The #NovacytTeam

+++

Is DA influencing new ways to spread the word on Novacyt products already?
Good stuff if so.

risehall1 -
" Setting up a US subsidiary and office was a big step forward"

I agree that setting up a US entity that pays Federal taxes is good for business.

I believe one of the reasons that Uncle Sam prefers to buy US goods and services,
is that he will be in receipt of corporate taxes from those US companies winning the contracts he offers.

It's a shame that Boris can't see this approach when ordering so much garbage from China.